These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 2181268)

  • 21. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H; Sabouraud O
    Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How to clinically approach involuntary movements].
    Shibasaki H
    Rinsho Shinkeigaku; 2003 Nov; 43(11):752-5. PubMed ID: 15152456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Movement disorders in complex regional pain syndrome.
    van Hilten JJ
    Pain Med; 2010 Aug; 11(8):1274-7. PubMed ID: 20704676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic considerations in movement disorders.
    Wszolek ZK; Pfeiffer RF
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):324-30. PubMed ID: 1623259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
    [No Abstract]   [Full Text] [Related]  

  • 27. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J; Orman J
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Movement Disorders in Chronic Kidney Disease - A Descriptive Review.
    Safarpour Y; Vaziri ND; Jabbari B
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105408. PubMed ID: 33139171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Movement disorders phenomenology in focal motor seizures.
    Fasano A; Di Bonaventura C; Bove F; Espay AJ; Morgante F; Fabbrini G; Munhoz RP; Andrade D; Borlot F; Bui E; Di Gennaro G; Iorio R; Katzberg H; Luigetti M; Striano P; Defazio G; Berardelli A
    Parkinsonism Relat Disord; 2019 Apr; 61():161-165. PubMed ID: 30361137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Hunter C; Jankovic J
    Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hyperkinetic movement disorders.
    Jankovic J
    Lancet Neurol; 2009 Sep; 8(9):844-56. PubMed ID: 19679276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6: Movement disorders II: the hyperkinetic disorders.
    Rice JE; Thompson PD
    Med J Aust; 2001 Apr; 174(8):413-9. PubMed ID: 11346089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripherally induced movement disorders.
    Jankovic J
    Neurol Clin; 2009 Aug; 27(3):821-32, vii. PubMed ID: 19555833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Movement disorders in pregnancy.
    Bordelon YM; Smith M
    Semin Neurol; 2007 Nov; 27(5):467-75. PubMed ID: 17940926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Movement disorders ii: chorea, dystonia, myoclonus, and tremor.
    Mink JW; Zinner SH
    Pediatr Rev; 2010 Jul; 31(7):287-94; quiz 295. PubMed ID: 20595442
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU.
    Ali F; Wijdicks EF
    Neurocrit Care; 2020 Feb; 32(1):286-294. PubMed ID: 31732848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient tardive dystonia: overview and case presentation.
    Seeman MV; Clodman D; Remington G
    J Psychiatr Pract; 2008 Jul; 14(4):251-7. PubMed ID: 18664896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Movement disorders in neuro-metabolic diseases.
    Gouider-Khouja N; Kraoua I; Benrhouma H; Fraj N; Rouissi A
    Eur J Paediatr Neurol; 2010 Jul; 14(4):304-7. PubMed ID: 20015670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
    Frattola L; Albizzati MG; Bassi S; Spano PF; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():381-6. PubMed ID: 6446848
    [No Abstract]   [Full Text] [Related]  

  • 40. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
    Simpson GM; Yadalam KG; Stephanos MJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.